Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug designation to it's MST-188 drug candidate, a potential treatment for sickle cell disease. The decision gives MSTX 10 years of marketing exclusivity, and follows a similar positive opinion by the Committee for Orphan Medicinal Products. The company says it expects to now pursue strategic alliances "more aggressively."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs